Amgen (AMGN) Share-based Compensation Growth (3y) (2012 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Stock Comp. Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
- |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
7.06% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
-0.66% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
12.36% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
8.46% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
16.86% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
9.73% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
37.34% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
6.17% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
16.86% |
| Dec 31, 2018 |
2.84% |
| Sep 30, 2018 |
-2.08% |
| Jun 30, 2018 |
1.10% |
| Mar 31, 2018 |
-8.29% |
| Dec 31, 2017 |
-7.10% |
| Sep 30, 2017 |
-5.11% |
| Jun 30, 2017 |
-5.01% |
| Mar 31, 2017 |
-11.65% |
| Dec 31, 2016 |
-3.49% |
| Sep 30, 2016 |
-6.02% |
| Jun 30, 2016 |
-8.07% |
| Mar 31, 2016 |
-17.32% |
| Dec 31, 2015 |
-4.20% |
| Sep 30, 2015 |
-3.41% |
| Jun 30, 2015 |
-5.01% |
| Mar 31, 2015 |
-2.27% |
| Dec 31, 2014 |
3.36% |
| Sep 30, 2014 |
13.20% |
| Jun 30, 2014 |
4.91% |
| Mar 31, 2014 |
4.15% |
| Dec 31, 2013 |
-1.94% |
| Sep 30, 2013 |
6.84% |
| Jun 30, 2013 |
4.55% |
| Mar 31, 2013 |
10.60% |
| Dec 31, 2012 |
6.66% |
| Sep 30, 2012 |
1.90% |
| Jun 30, 2012 |
17.94% |
| Mar 31, 2012 |
8.33% |
